Compare CF & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CF | GMAB |
|---|---|---|
| Founded | 1946 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | 3088 |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8B | 16.5B |
| IPO Year | 2005 | N/A |
| Metric | CF | GMAB |
|---|---|---|
| Price | $122.33 | $26.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $118.93 | $39.56 |
| AVG Volume (30 Days) | ★ 2.9M | 1.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.58% | N/A |
| EPS Growth | ★ 33.09 | N/A |
| EPS | ★ 3.98 | N/A |
| Revenue | ★ $7,084,000,000.00 | N/A |
| Revenue This Year | $3.85 | $17.85 |
| Revenue Next Year | N/A | $16.04 |
| P/E Ratio | $30.63 | ★ $1.90 |
| Revenue Growth | ★ 19.34 | N/A |
| 52 Week Low | $75.42 | $20.23 |
| 52 Week High | $141.96 | $35.43 |
| Indicator | CF | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 49.41 |
| Support Level | $112.18 | $25.34 |
| Resistance Level | $131.00 | $29.64 |
| Average True Range (ATR) | 5.11 | 0.75 |
| MACD | -0.29 | 0.05 |
| Stochastic Oscillator | 51.10 | 52.21 |
CF Industries is a leading producer and distributor of nitrogen, which is primarily used in fertilizers. The company operates nitrogen manufacturing plants primarily in North America. CF also produces nitrogen in the United Kingdom and holds a joint venture interest in a nitrogen production facility in Trinidad and Tobago. CF makes nitrogen primarily using low-cost US natural gas as its feedstock, making the company one of the lowest-cost nitrogen producers globally. It is also investing in carbon-free blue and green ammonia, which can be used as an alternative fuel to hydrogen or as a means to transport hydrogen.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.